Listen and follow our podcasts on:

Eisai Europe Limited

Podcast with Dr Jaume Capdevila and Dr Rachel van Leeuwaarde discussing the use of multi-kinase inhibitors (MKIs), in particular VEGFR-TKIs in patients with radioactive iodine refractory differentiated thyroid cancer (DTC).

 

In this episode, the two experts discuss key trials (SELECT, DECISION and COSMIC-311) and efficacy parameters of the current VEGFR-TKIs (lenvatinib, sorafenib and cabozantinib), how to manage toxicity whilst trying to optimise treatment outcomes and preserving always patients’ quality of life. They also discuss treatment strategies, when to start systemic treatment, which drug should be used first and how to sequence therapies. To close the podcast they take a look at ongoing clinical trials with other treatments in development for DTC.

This NET CONNECT podcast series is also available on CastosSpotifyApple Podcasts, and Google Podcasts.

Dr Jaume Capdevila obtained his medical degree from the University of Lleida, in Catalonia, Spain. In 2000-2001 he held a fellowship in the department of biochemistry and molecular biology at the University of Lleida. From 2002 to 2006 he attended a specialization in medical oncology at the Santa Creu i Sant Pau University Hospital, Barcelona and since 2006 served as medical oncologist at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Since early 2013 he is also leading the gastrointestinal and endocrine tumor unit at Teknon Cancer Institute. He is involved in research and treatment of patients with gastrointestinal cancer and endocrine tumors as well as in early-drug development. He has published over 82 articles in peer-reviewed journals and several book chapters. He is an active member of several oncology societies (ASCO, ENETS, EORTC, SEOM, TTD, GEMCAD, GETNE, and GETHI) and actively participates in national and international trials. He is member of the advisory board of the European Neuroendocrine Tumor Society (ENETS), Secretary and Treasurer of the Spanish Task Force for neuroendocrine tumors (Grupo Español de Tumores Neuroendocrinos, GETNE) and funding member and Treasurer of the Spanish Task Force Group for Research in Orphan and Rare Tumors (Grupo Español de Tumores Huérfanos e Infrecuentes, GETHI). He is also a medical oncologist member of the Thyroid Cancer Working Group within the Spanish Society of Endocrinology and Nutrition (SEEN).

Dr Jaume Capdevila has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Bayer, Eisai, Merck, Novartis, Ipsen, Pfizer and Sanofi. 

Dr Rachel van Leeuwaarde is an endocrinologist at the department of Endocrine Oncology at the University Medical Center of Utrecht, The Netherlands. She graduated cum laude from the Vrije University in Amsterdam and completed her Internal Medicine residency at the University Medical Center of Utrecht. During her endocrinology fellowship she developed an interest in endocrine oncology. Currently she is a staff member at the department of Endocrine Oncology at the University Medical Center of Utrecht and the Antoni van Leeuwenhoek hospital in Amsterdam. During her PhD trajectory on Multiple Endocrine Neoplasia Type 1, she completed a master in Epidemiology at the Julius Center for Health Sciences and Primary Care at the University Medical Center of Utrecht. Her PhD study was on “The impact of screening in Multiple Endocrine Neoplasia type 1”. Dr van Leeuwaarde’s research focusses on endocrine tumor syndromes such as Multiple Endocrine Neoplasia type 1 & 2 and Von Hippel Lindau disease with a special interest in screening and the health related quality of life in these syndromes.

Listen and follow our podcasts on:

Eisai Europe Limited

Podcast with Dr Jaume Capdevila and Dr Rachel van Leeuwaarde discussing the use of multi-kinase inhibitors (MKIs), in particular VEGFR-TKIs in patients with radioactive iodine refractory differentiated thyroid cancer (DTC).

 

In this episode, the two experts discuss key trials (SELECT, DECISION and COSMIC-311) and efficacy parameters of the current VEGFR-TKIs (lenvatinib, sorafenib and cabozantinib), how to manage toxicity whilst trying to optimise treatment outcomes and preserving always patients’ quality of life. They also discuss treatment strategies, when to start systemic treatment, which drug should be used first and how to sequence therapies. To close the podcast they take a look at ongoing clinical trials with other treatments in development for DTC.

This NET CONNECT podcast series is also available on CastosSpotifyApple Podcasts, and Google Podcasts.

Dr Jaume Capdevila obtained his medical degree from the University of Lleida, in Catalonia, Spain. In 2000-2001 he held a fellowship in the department of biochemistry and molecular biology at the University of Lleida. From 2002 to 2006 he attended a specialization in medical oncology at the Santa Creu i Sant Pau University Hospital, Barcelona and since 2006 served as medical oncologist at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Since early 2013 he is also leading the gastrointestinal and endocrine tumor unit at Teknon Cancer Institute. He is involved in research and treatment of patients with gastrointestinal cancer and endocrine tumors as well as in early-drug development. He has published over 82 articles in peer-reviewed journals and several book chapters. He is an active member of several oncology societies (ASCO, ENETS, EORTC, SEOM, TTD, GEMCAD, GETNE, and GETHI) and actively participates in national and international trials. He is member of the advisory board of the European Neuroendocrine Tumor Society (ENETS), Secretary and Treasurer of the Spanish Task Force for neuroendocrine tumors (Grupo Español de Tumores Neuroendocrinos, GETNE) and funding member and Treasurer of the Spanish Task Force Group for Research in Orphan and Rare Tumors (Grupo Español de Tumores Huérfanos e Infrecuentes, GETHI). He is also a medical oncologist member of the Thyroid Cancer Working Group within the Spanish Society of Endocrinology and Nutrition (SEEN).

Dr Jaume Capdevila has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Bayer, Eisai, Merck, Novartis, Ipsen, Pfizer and Sanofi. 

Dr Rachel van Leeuwaarde is an endocrinologist at the department of Endocrine Oncology at the University Medical Center of Utrecht, The Netherlands. She graduated cum laude from the Vrije University in Amsterdam and completed her Internal Medicine residency at the University Medical Center of Utrecht. During her endocrinology fellowship she developed an interest in endocrine oncology. Currently she is a staff member at the department of Endocrine Oncology at the University Medical Center of Utrecht and the Antoni van Leeuwenhoek hospital in Amsterdam. During her PhD trajectory on Multiple Endocrine Neoplasia Type 1, she completed a master in Epidemiology at the Julius Center for Health Sciences and Primary Care at the University Medical Center of Utrecht. Her PhD study was on “The impact of screening in Multiple Endocrine Neoplasia type 1”. Dr van Leeuwaarde’s research focusses on endocrine tumor syndromes such as Multiple Endocrine Neoplasia type 1 & 2 and Von Hippel Lindau disease with a special interest in screening and the health related quality of life in these syndromes.

Programme summary
  • clock Duration 20 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe Limited
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe Limited
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Ipsen and from Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe Limited
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe Limited
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Ipsen and from Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ASCO 2025

Coming Soon: Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Dr Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock 1 MIN
  • calendar May 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA